Article
First-Line Cetuximab Monotherapy in KRAS/NRAS/BRAF Mutation-Negative Colorectal Cancer Patients.
Clinical drug investigation - 1 Jun 2018
Moiseyenko Vladimir M, Moiseyenko Fedor V, Yanus Grigoriy A, Kuligina Ekatherina Sh, Sokolenko Anna P, Bizin Ilya V, Kudriavtsev Alexey A, Aleksakhina Svetlana N, Volkov Nikita M, Chubenko Vyacheslav A, Kozyreva Kseniya S, Kramchaninov Mikhail M, Zhuravlev Alexandr S, Shelekhova Kseniya V, Pashkov Denis V, Ivantsov Alexandr O, Venina Aigul R, Sokolova Tatyana N, Preobrazhenskaya Elena V, Mitiushkina Natalia V, Togo Alexandr V, Iyevleva Aglaya G, Imyanitov Evgeny N
Abstract excerpt
BACKGROUND: Colorectal carcinomas (CRCs) are sensitive to treatment by anti-epidermal growth factor receptor (EGFR) antibodies only if they do not carry activating mutations in down-stream EGFR targets (KRAS/NRAS/BRAF). Most clinical trials for chemo-naive CRC patients involved combination of targeted agents and chemotherapy, while single-agent cetuximab or panitumumab studies included either heavily pretreated...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.